Targeting BCMA in Multiple Myeloma: Evidence-Based Guidance for Current and Near Future Clinical Integration
  • CME

Read this module from Nina Shah, MD, to learn more about how BCMA-targeted agents work in multiple myeloma and how you can use these agents in clinical practice to improve patient outcomes.
Nina Shah, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: April 4, 2022 Expiration: April 3, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Understand the clinical rationale for incorporating BCMA-targeted agents into the treatment plan for patients with multiple myeloma
  • Differentiate and compare the available efficacy, safety, and tolerability data among the different BCMA-targeted therapies in patients with multiple myeloma
  • Identify patients with multiple myeloma who are likely to benefit from treatment with a specific BCMA-targeted therapy based on patient and tumor characteristics, patient preference, and sBCMA
  • Evaluate the role of sBCMA on treatment efficacy and mechanisms of resistance that can impact sequential use of BCMA targeting agents
  • Monitor and mitigate potential adverse events from anti-BCMA therapy in patients with multiple myeloma, including but not limited to ocular toxicity, cytokine release syndrome, and neurotoxicity
  • Select patients with relapsed/refractory multiple myeloma who would be eligible for enrollment on clinical trials of therapies targeting BCMA

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Pfizer, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Nina Shah, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Nina Shah, MD, has disclosed that she has received research funding from Bluebird Bio, Celgene/Bristol-Myers Squibb, Nektar, Poseida, Precision Biosciences, Sutro Biopharma, and Teneobio and has served as a consultant, advisor, and speaker for Amgen, CareDx, CSL Behring, Indapta Therapeutics, GlaxoSmithKline, Karyopharm, Kite, Oncopeptides, and Sanofi.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Anna Poppa

Editorial Contributor

Anna Poppa has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed he had individual publicly traded stocks/stock options in AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hematologist-oncologists and other healthcare professionals who care for patients with multiple myeloma.

Goal

The goal of this activity is to improve learners’ knowledge of and competence in applying practice-changing clinical data and expert recommendations to integrate the use of BCMA-targeted agents for their patients with multiple myeloma.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 04, 2022, through April 03, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable slideset with highlights from key hematologic cancers as presented at EHA 2022 Congress, from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 30, 2022

Experts discuss important new data from ASCO 2022 that may impact treatment for chronic lymphocytic leukemia and mantle cell lymphoma, from Clinical Care Options (CCO)

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: June 30, 2022

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care

Jesús G. Berdeja, MD Caron A. Jacobson, MD Released: June 30, 2022

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 27, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings